Bazı Dioksaborepin Türevlerinin Sentezi ve Antimikrobiyal Aktivite Tayini

Abstract

ÖzBu çalışmanın amacı, bazı dioksaborepin bileşiklerini (2a-c) sentezlemek ve (2a) bileşiği için çeşitli mikroorganizmalara karşı antimikrobiyal aktivite sonuçlarını değerlendirmektir. Mikrodilüsyon yöntemi için Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 25923), Echerichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853), Streptococcus mutans (ATCC 25175) ve Candida albicans (ATCC 90028) kullanılmıştır. Dioksaborepin bileşiği (2a) özellikle hastane enfeksiyonuna neden olabilen P. aeruginosa'ya karşı iyi sonuç vermiştir. Dioksaborepin bileşiği (2a) Gram negatif ve Gram pozitif bakteriler ve mantara karşı aktivite göstermiştir. Bu çalışmadaki sonuçlara göre günümüzde, bor içeren yeni bileşiklerin sentezi ve aktivite testleri önemli bir yer tutmaktadır. Bu tür bileşikler geliştirilebilir ve gelecekte daha etkili, yeni antibakteriyel ve antifungal madde tasarımında kullanılabilirler.

Molecular Docking Studies of Boron‐Containing Compounds as Dual Inhibitors of SARS‐Cov‐2 Spike Receptor Binding Domain/ACE2 Complex and Main Protease and ADMET Investigations

“…The ligands, dioxaborepine and oxadiazaborole derivatives, used in the study have been synthesized and characterized already [23,25,26] . All ligands were optimized initially by starting with PM6 [78] semi‐empirical method and followed by using B3LYP/6‐31+g(d,p) level of theory and basis set with the DFT method [79,80,81] (Supporting Information Table SI 4.and 5.).…”

“…The ligands, dioxaborepine and oxadiazaborole derivatives, used in the study have been synthesized and characterized already. [23,25,26] All ligands were optimized initially by starting with PM6 [78] semiempirical method and followed by using B3LYP/6-31 + g(d,p) level of theory and basis set with the DFT method [79,80,81] (Supporting Information Table SI 4.and 5.). The frequency calculations which are performed at same level of theory showed none imaginary frequencies for all the structures which is the evidence of reaching a global minimum.…”

“…Boron chemistry is one of the most important subjects in organic chemistry, and it attracts increasing attention because of their easy and efficient ways to prepare organoboron (C−B bond formation) reagents which is an important reagent family in organic synthesis [16] . Boron atom‐containing compounds (oxadiazaboroles, oxaboroles, dioxaborepines, heterocyclic aminoborons, cyclic boronates, benzoxaboroles, boronic acid esters, aromatic boronic acids) in the medicinal chemistry are showing anticancer, antibacterial, antiviral, antifungal, antiparasitic, anti‐inflammatory, antituberculosis, antidermatophytic and antifertility activities [17,18,19,20,21,22,23,24,25,26,27,28] . Food and Drug Administration (FDA)‐approved boron‐containing drugs are bortezomib (a boronic acid‐containing drug), tavaborole, ixazomib, crisaborole, vaborbactam, respectively.…”

“…[16] Boron atom-containing compounds (oxadiazaboroles, oxaboroles, dioxaborepines, heterocyclic aminoborons, cyclic boronates, benzoxaboroles, boronic acid esters, aromatic boronic acids) in the medicinal chemistry are showing anticancer, antibacterial, antiviral, antifungal, antiparasitic, antiinflammatory, antituberculosis, antidermatophytic and antifertility activities. [17,18,19,20,21,22,23,24,25,26,27,28] Food and Drug Administration (FDA)-approved boron-containing drugs are bortezomib (a boronic acid-containing drug), tavaborole, ixazomib, crisaborole, vaborbactam, respectively. Other boron-containing drug candidates (talabostat (PT100), dutogliptin (PHX-1149), acoziborole (SCYX-7158; AN5568), taniborbactam, AN2898, QPX7728, GSK656, GSK2878175) are also in various stages of clinical trials.…”

“…The substituted heterocyclic dioxaborepines and oxadiazaboroles (codes of compounds in references/codes of compounds in current study: 4 a-4 m [26] /d4 a-d4 m, 2 a-2 c [23] /d4 n-d4 p, 4 a-4 r [25] /o4 a-o4 r and 7 a-7 s [25] /o7 a-o7 s) with significant antimicrobial activities [23,25,26,48] those used in our study are organoboron compounds whose effects have not been examined against SARS-CoV-2 before. In addition to defining the ADMET properties of related compounds, molecular docking studies were performed to obtain binding poses and properties of these ligands in binding sites of SARS-CoV-2 Spike RBD/ACE2 complex and M PRO proteins.…”